UBS Group’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,920
| Closed | -$15.8K | – | 10958 |
|
|
2024
Q4 | $15.8K | Buy |
7,920
+1,777
| +29% | +$3.6K | ﹤0.01% | 8026 |
|
|
2024
Q3 | $15.3K | Buy |
6,143
+5,470
| +813% | +$15.7K | ﹤0.01% | 7517 |
|
|
2024
Q2 | $2.36K | Buy |
+673
| New | +$3.91K | ﹤0.01% | 8372 |
|
|
2024
Q1 | – | Sell |
-14
| Closed | -$174 | – | 10179 |
|
|
2023
Q4 | $174 | Buy |
+14
| New | +$328 | ﹤0.01% | 8845 |
|
|
2023
Q1 | – | Sell |
-17
| Closed | -$1.44K | – | 10596 |
|
|
2022
Q4 | $1.44K | Buy |
17
+2
| +13% | +$363 | ﹤0.01% | 9864 |
|
|
2022
Q3 | $11K | Sell |
15
-13
| -46% | -$4.16K | ﹤0.01% | 8343 |
|
|
2022
Q2 | $9K | Hold |
28
| – | – | ﹤0.01% | 8190 |
|
|
2022
Q1 | $15K | Buy |
28
+4
| +17% | +$2.99K | ﹤0.01% | 7862 |
|
|
2021
Q4 | $25K | Buy |
24
+18
| +300% | +$26K | ﹤0.01% | 7597 |
|
|
2021
Q3 | $10K | Buy |
6
+5
| +500% | +$10.3K | ﹤0.01% | 8027 |
|
|
2021
Q2 | $3K | Sell |
1
-4
| -80% | -$19.7K | ﹤0.01% | 8850 |
|
|
2021
Q1 | $34K | Buy |
5
+2
| +67% | +$13.7K | ﹤0.01% | 6907 |
|
|
2020
Q4 | $23K | Hold |
3
| – | – | ﹤0.01% | 6849 |
|
|
2020
Q3 | $32K | Sell |
3
-3
| -50% | -$36.5K | ﹤0.01% | 5956 |
|
|
2020
Q2 | $68K | Buy |
6
+4
| +200% | +$45.1K | ﹤0.01% | 5618 |
|
|
2020
Q1 | $18K | Hold |
2
| – | – | ﹤0.01% | 6562 |
|
|
2019
Q4 | $19K | Sell |
2
-2
| -50% | -$14K | ﹤0.01% | 6904 |
|
|
2019
Q3 | $28K | Sell |
4
-1
| -20% | -$6.81K | ﹤0.01% | 6534 |
|
|
2019
Q2 | $36K | Buy |
5
+1
| +25% | +$5.79K | ﹤0.01% | 6197 |
|
|
2019
Q1 | $23K | Buy |
4
+1
| +33% | +$6.38K | ﹤0.01% | 6196 |
|
|
2018
Q4 | $17K | Buy |
3
+1
| +50% | +$4.78K | ﹤0.01% | 6917 |
|
|
2018
Q3 | $7K | Sell |
2
-2
| -50% | -$8.22K | ﹤0.01% | 7349 |
|
|
2018
Q2 | $18K | Buy |
4
+1
| +33% | +$4.64K | ﹤0.01% | 6782 |
|
|
2018
Q1 | $17K | Sell |
3
-6
| -67% | -$29.7K | ﹤0.01% | 6522 |
|
|
2017
Q4 | $35K | Buy |
+9
| New | +$45.9K | ﹤0.01% | 6129 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$9K | – | 8059 |
|
|
2017
Q2 | $9K | Buy |
+1
| New | +$9K | ﹤0.01% | 6855 |
|
UBS Group's ATXI Position: Q1 2025 in Review
UBS Group sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2025, closing a stake of 7,920 shares — an estimated $15.8K sold.
UBS Group first reported a position in ATXI in Q2 2017 and held it in 26 quarters. The position peaked at $68K in Q2 2020. 0 funds tracked by Wall St. Rank hold ATXI as of Q1 2025.
- UBS Group reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 7,920 Avenue Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $15.8K.
- UBS Group first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2017 and held it in 26 quarters.
- UBS Group's Avenue Therapeutics, Inc. Common Stock position peaked at $68K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.